Nebulized Colistin for Gram Negative VAP Prevention.
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Colistin is used as an elective treatment of infections of multi drug resistant gram negative
bacteria. Until now colistin is used in the therapeutic regimen of these infections
intravenous or nebulized. There are a plenty of studies about the efficacy of nebulized
colistin in the therapy of pseudomonas aeruginosa pneumonia in patients with cystic fibrosis
and in the therapy of ventilator associated pneumonia in ICU. On the other hand there are
only a few studies about the use of nebulized colistin in the prevention of ventilator
associated pneumonia whereas the role of nebulized colistin in the prevention of severe forms
of pneumonia such as VAP due to multi drug resistant gram negative bacteria are limited.
This double blinded randomized trial aim to investigate the effect of nebulized colistin on
the incidence of patients with due to gram negative bacteria in the ICU compared to nebulized
normal saline.